177 related articles for article (PubMed ID: 18322167)
81. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.
Vidal-Castiñeira JR; López-Vázquez A; Díaz-Peña R; Alonso-Arias R; Martínez-Borra J; Pérez R; Fernández-Suárez J; Melón S; Prieto J; Rodrigo L; López-Larrea C
J Virol; 2010 Jan; 84(1):475-81. PubMed ID: 19846535
[TBL] [Abstract][Full Text] [Related]
82. Costimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis C.
Larrubia JR; Benito-Martínez S; Miquel J; Calvino M; Sanz-de-Villalobos E; Parra-Cid T
World J Gastroenterol; 2009 Nov; 15(41):5129-40. PubMed ID: 19891011
[TBL] [Abstract][Full Text] [Related]
83. Immunological and virological predictors of outcome during interferon-alpha therapy of chronic hepatitis C.
Saito H; Ebinuma H; Satoh I; Miyaguchi S; Tada S; Iwabuchi N; Kumagai N; Tsuchimoto K; Morizane T; Ishii H
J Viral Hepat; 2000 Jan; 7(1):64-74. PubMed ID: 10718945
[TBL] [Abstract][Full Text] [Related]
84. CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment.
Legrand E; Neau D; Galperine T; Trimoulet P; Moreau JF; Pitard V; Lacut JY; Ragnaud JM; Dupon M; Le Bail B; Bernard N; Schvoerer E; Houghton M; Fleury H; Lafon ME
J Infect Dis; 2002 Aug; 186(3):302-11. PubMed ID: 12134226
[TBL] [Abstract][Full Text] [Related]
85. Impaired hepatitis B vaccine responses during chronic hepatitis C infection: involvement of the PD-1 pathway in regulating CD4(+) T cell responses.
Moorman JP; Zhang CL; Ni L; Ma CJ; Zhang Y; Wu XY; Thayer P; Islam TM; Borthwick T; Yao ZQ
Vaccine; 2011 Apr; 29(17):3169-76. PubMed ID: 21376795
[TBL] [Abstract][Full Text] [Related]
86. Programmed death-1 affects suppressor of cytokine signaling-1 expression in T cells during hepatitis C infection.
Frazier AD; Zhang CL; Ni L; Ma CJ; Zhang Y; Wu XY; Atia AN; Yao ZQ; Moorman JP
Viral Immunol; 2010 Oct; 23(5):487-95. PubMed ID: 20883163
[TBL] [Abstract][Full Text] [Related]
87. HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals.
Rallón NI; Soriano V; Restrepo C; García-Samaniego J; Labarga P; López M; Peris A; González-Lahoz J; Benito JM
J Acquir Immune Defic Syndr; 2011 May; 57(1):1-8. PubMed ID: 21786458
[TBL] [Abstract][Full Text] [Related]
88. Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.
Söderholm J; Waldenström J; Askarieh G; Pilli M; Bochud PY; Negro F; Pawlotsky JM; Zeuzem S; Ferrari C; Norkrans G; Wejstål R; Westin J; Neumann AU; Haagmans BL; Lindh M; Missale G; Hellstrand K; Lagging M
PLoS One; 2013; 8(2):e56991. PubMed ID: 23437290
[TBL] [Abstract][Full Text] [Related]
89. Up-regulation of programmed death-1 expression on beryllium-specific CD4+ T cells in chronic beryllium disease.
Palmer BE; Mack DG; Martin AK; Gillespie M; Mroz MM; Maier LA; Fontenot AP
J Immunol; 2008 Feb; 180(4):2704-12. PubMed ID: 18250483
[TBL] [Abstract][Full Text] [Related]
90. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
Van den Eynde E; Crespo M; Esteban JI; Jardi R; Ribera E; Carbonell J; Rodríguez-Frias F; Falco V; Curran A; Imaz A; Villar del Saz S; Ocaña I; Esteban R; Pahissa A
Clin Infect Dis; 2009 Apr; 48(8):1152-9. PubMed ID: 19275492
[TBL] [Abstract][Full Text] [Related]
91. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1).
Fuller MJ; Callendret B; Zhu B; Freeman GJ; Hasselschwert DL; Satterfield W; Sharpe AH; Dustin LB; Rice CM; Grakoui A; Ahmed R; Walker CM
Proc Natl Acad Sci U S A; 2013 Sep; 110(37):15001-6. PubMed ID: 23980172
[TBL] [Abstract][Full Text] [Related]
92. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.
Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA
Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060
[TBL] [Abstract][Full Text] [Related]
93. Natural killer cells and hepatitis C: natural killer p46 expression linked to antiviral and antifibrotic activity.
Heeg M; Thimme R
Hepatology; 2012 Oct; 56(4):1197-200. PubMed ID: 22610395
[No Abstract] [Full Text] [Related]
94. Treating hepatitis C in African Americans.
Jeffers LJ
Liver Int; 2007 Apr; 27(3):313-22. PubMed ID: 17355451
[TBL] [Abstract][Full Text] [Related]
95. Study looks at HCV therapy responses.
AIDS Patient Care STDS; 2002 Feb; 16(2):100. PubMed ID: 11892630
[No Abstract] [Full Text] [Related]
96. Engineering modular intracellular protein sensor-actuator devices.
Siciliano V; DiAndreth B; Monel B; Beal J; Huh J; Clayton KL; Wroblewska L; McKeon A; Walker BD; Weiss R
Nat Commun; 2018 May; 9(1):1881. PubMed ID: 29760420
[TBL] [Abstract][Full Text] [Related]
97. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma.
Beldi-Ferchiou A; Lambert M; Dogniaux S; Vély F; Vivier E; Olive D; Dupuy S; Levasseur F; Zucman D; Lebbé C; Sène D; Hivroz C; Caillat-Zucman S
Oncotarget; 2016 Nov; 7(45):72961-72977. PubMed ID: 27662664
[TBL] [Abstract][Full Text] [Related]
98. Endotoxemia Associated with Liver Disease Correlates with Systemic Inflammation and T Cell Exhaustion in Hepatitis C Virus Infection.
Shive CL; Kowal CM; Desotelle AF; Nguyen Y; Carbone S; Kostadinova L; Davitkov P; O'Mara M; Reihs A; Siddiqui H; Wilson BM; Anthony DD
Cells; 2023 Aug; 12(16):. PubMed ID: 37626844
[TBL] [Abstract][Full Text] [Related]
99. PD-1 expression on mouse intratumoral NK cells and its effects on NK cell phenotype.
Wagner AK; Kadri N; Tibbitt C; van de Ven K; Bagawath-Singh S; Oliinyk D; LeGresley E; Campbell N; Trittel S; Riese P; Ribacke U; Sandalova T; Achour A; Kärre K; Chambers BJ
iScience; 2022 Oct; 25(10):105137. PubMed ID: 36185379
[TBL] [Abstract][Full Text] [Related]
100. Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma.
Ameli F; Shajareh E; Mokhtari M; Kosari F
BMC Cancer; 2022 Aug; 22(1):848. PubMed ID: 35922773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
